Immunogene Therapy for Murine Melanoma Using Recombinant Adenoviral Vectors Expressing Melanoma-Associated Antigens

Molecular Therapy

Volumn 1, Issue 3, 2000, Pages 275-284

  Perricone, Michael A ^a   Claussen, Kirsten A ^a   Smith, Karen A ^a   Kaplan, Johanne M ^a   Piraino, Susan ^a   Shankara, Srinivas ^a   Roberts, Bruce L ^a  

^a Genzyme Molecular Oncology   (United States)

Author keywords

Melanoma; immunotherapy; melanoma associated antigen (MAA); cytotoxic T lymphocyte (CTL); gene therapy; vaccine

Indexed keywords

DOPACHROME ISOMERASE; ISOMERASE; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MEMBRANE PROTEIN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADENOVIRUS; ANIMAL; ARTICLE; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; INJECTION; MELANOMA; METABOLISM; MOUSE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; INJECTIONS; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; TUMOR CELLS, CULTURED;

EID: 0034151424     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0029     Document Type: Article

References (33)

1. Bloom M. B., Perry-Lalley D., Robbins P. F., Li Y., El-Gamil M., Rosenberg S. A. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:1997;453.
2. Coulie P. G., Brichard V., Pel A. V., Wolfel T., Schneider J., Traversari C., Mattei S., DePlaen E., Lurquin C., Szikora J.-P., Reauld J.-C., Boon T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:1994;35-42.
3. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Rivoltini L., Topalian S. L., Miki T., Rosenberg S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA. 91:1994;3515-3519.
4. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Sakaguchi K., Apella W., Yannelli J. R., Adema G. J., Miki T., Rosenberg S. A. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA. 91:1994;6458-6462.
5. Robbins P. F., El-Gamil M., Kawakami Y., Stevens E., Yannelli J. R., Rosenberg S. A. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54:1994;3124-3126.
6. Wang R. F., Parkhurst M. R., Kawakami Y., Robbins P. F., Rosenberg S. A. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183:1996;1131-1140.
7. Wang R. F., Robbins P. F., Kawakami Y., Kang X. Q., Rosenberg S. A. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181:1995;799-804.
8. Linehan D. C., Goedegebuure P. S., Eberlein T. J. Vaccine therapy for cancer. Ann. Surg. Oncol. 342:1994;219-228.
9. Rosenberg S. A. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J. Natl. Cancer Inst. 88:1996;1635-1644.
10. Tuting T., Storkus W. J., Lotze M. T. Gene-based strategies for the immunotherapy of cancer. J. Mol. Med. 75:1997;478-491.
11. Juillard V., Villefroy P., Godfrin D., Pavirani A., Venet A., Guillet J. G. Long-term humoral and cellular immunity induced by a single immunization with replication-defective recombinant vector. Eur. J. Immunol. 25:1995;3467-3473.
12. Warnier G., Duffour M.-T., Uyttenhove C., Gajewski T. F., Lurquin C., Haddada H., Perricaudet M., Boon T. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int. J. Cancer. 67:1996;303-310.
13. Zhai Y., Yang J. C., Kawakami Y., Spiess P., Wadsworth S. C., Cardoza L. M., Couture L. A., Smith A. E., Rosenberg S. A. Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol. 156:1996;700-710.
14. Armentano D., Sookdeo C. C., Hehir K. M., Gregory R. J., George J. A. S., Prince G. A., Wadsworth S. C., Smith A. E. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum. Gene Ther. 6:1995;1343-1353.
15. Lee E. R., Marshall J., Siegel C. S., Jiang C., Yew N. S., Nichols M. R., Nietupski J. B., Ziegler R. J., Lane M., Wang K. X., Wan N. C., Scheule R. K., Harris D. J., Smith A. E., Cheng S. H. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum. Gene Ther. 7:1996;1701-1717.
16. Poste G., Fidler I. J. The pathogenesis of cancer metastasis. Nature. 283:1980;139-146.
17. Kaplan J. M., Armentano D., Sparer T. E., Wynn S. G., Peterson P. A., Wadsworth S. C., Couture K. K., Pennington S. E., St. George J. A., Goding L. R., Smith A. E. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther. 8:1997;45-56.
18. Overwijk W. W., Tsung A., Irvine K. R., Parkhurst M. R., Goletz T. J., Tsung K., Carroll M. W., Liu C., Moss B., Rosenberg S. A., Restifo N. P. gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:1998;277-286.
19. Czerkinsky C. C., Andersson G., Ekre H.-P., Nilsson L. A., Klareskog L., Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Methods. 110:1988;29.
20. Taguchi T., McGhee J. R., Coffman R. L., Beagley K. W., Eldridge J. H., Takatsu K., Kiyono H. Detection of individual mouse splenic T cells producing IFN-γ and IL-5 using the enzyme-linked immunospot (ELISPOT) assay. J. Immunol. Methods. 128:1990;65-73.
21. Wan Y., Bramson J., Carter R., Graham F., Gauldie J. Dendritic cell transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum. Gene Ther. 8:1997;1355-1363.
22. Chen P. W., Wang M., Bronte V., Zhai Y., Rosenberg S. A., Restifo N. P. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156:1996;224-231.
23. Li W., Berencsi K., Basak S., Somasundaram R., Ricciardi R. P., Gonczol E., Zaloudik J., Linnenbach A., Maruyama H., Miniou P., Herlyn D. Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice. J. Immunol. 159:1997;763-769.
24. Kaplan J. M., Yu Q., Piraino S. T., Pennington S. E., Shankara S., Woodworth L. A., Roberts B. Induction of antitumor immunity using dendritic cells transduced with adenovirus vector encoding endogenous tumor-associated antigens. J. Immunol. 163:1999;699-707.
25. Rosenberg S. A., Zhai Y., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Restifo N. P., Seipp C. A., Einhorn J. H., Roberts B., White D. E. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90:1998;1894-1900.
26. Harvey B. G., Worgall S., Ely S., Leopold P. L., Crystal R. G. Cellular immune responses of healthy individuals to intradermal administration of an E1-E3-adenovirus gene transfer vector. Hum. Gene Ther. 10:1999;2823-2837.
27. Yang S., Darrow T. L., Vervaert C. E., Seigler H. F. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. Cell. Immunol. 179:1997;84-95.
28. Celluzzi C. M., Falo L. D. Jr. Cutting edge: Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol. 160:1998;3081-3085.
29. Gong J., Chen D., Kashiwaba M., Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3:1997;558-561.
30. Mayordomo J. I., Loftus D. J., Sakamoto H., DeCesare C. M., Appasamy P. M., Lotze M. T., Storkus W. J., Appella E., DeLeo A. B. Therapy of murine tumors with p53 wild-type mutant sequence peptide-based vaccines. J. Exp. Med. 183:1996;1357-1365.
31. Mayordomo J. I., Zorina T., Storkus W. J., Zitvogel L., Celluzzi C., Falo L. D., Melief C. J., Ildstad S. T., Kast W. M., De Leo A. B., Lotze M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nat. Med. 1:1995;1297-1302.
32. Furumura M., Sakai C., Potterf S. B., Vieira W. D., Barsh G. S., Hearing V. J. Characterization of genes modulated during pheomelanogenesis using differential display. Proc. Natl. Acad. Sci. USA. 95:1998;7374-7378.
33. Hirschowitz E. A., Leonard S., Song W., Ferris B., Leopold P. L., Lewis J. J., Bowne W. B., Wang S., Houghton A. N., Crystal R. G. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther. 5:1998;975-983.